Literature DB >> 12764067

Autosomal dominant restless legs syndrome maps on chromosome 14q.

Maria Teresa Bonati1, Luigi Ferini-Strambi, Paolo Aridon, Alessandro Oldani, Marco Zucconi, Giorgio Casari.   

Abstract

Restless legs syndrome (RLS) is a common neurological disorder characterized by an irresistible desire to move the extremities associated with paraesthesia/dysaesthesia. These symptoms occur predominantly at rest and worsen at night, resulting in nocturnal insomnia and chronic sleep deprivation. In this paper, we show significant evidence of linkage to a new locus for RLS on chromosome 14q13-21 region in a 30-member, three-generation Italian family affected by RLS and periodic leg movements in sleep (PLMS). This is the second RLS locus identified so far and the first consistent with an autosomal dominant inheritance pattern. The new RLS critical region spans 9.1 cM, between markers D14S70 and D14S1068. The maximum two-point log of odds ratio score value, of 3.23 at theta = 0.0, was obtained for marker D14S288. The accurate clinical evaluation of RLS-affected, as well as unaffected, family members allowed for the configuring of RLS as a phenotypic spectrum ranging from PLMS to RLS. Motor component, both while awake and during sleep, was an important aspect of the phenotype in the family analysed. The complementary clinical and genetic studies on multiplex families are likely to be of the utmost importance in unfolding the complete expressivity of RLS phenotype spectrum.

Entities:  

Mesh:

Year:  2003        PMID: 12764067     DOI: 10.1093/brain/awg137

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  47 in total

1.  Iron deficiency anemia in infancy exerts long-term effects on the tibialis anterior motor activity during sleep in childhood.

Authors:  Patricio Peirano; Cecilia Algarin; Rodrigo Chamorro; Mauro Manconi; Betsy Lozoff; Raffaele Ferri
Journal:  Sleep Med       Date:  2012-07-04       Impact factor: 3.492

2.  Restless legs syndrome: diagnostic assessment and the advantages and risks of dopaminergic treatment.

Authors:  Birgit Högl; Walter Paulus; Peter Clarenbach; Claudia Trenkwalder
Journal:  J Neurol       Date:  2006-08       Impact factor: 4.849

Review 3.  Genome-wide association studies of sleep disorders.

Authors:  David M Raizen; Mark N Wu
Journal:  Chest       Date:  2011-02       Impact factor: 9.410

4.  Recent advances in the diagnosis, genetics and treatment of restless legs syndrome.

Authors:  Claudia Trenkwalder; Birgit Högl; Juliane Winkelmann
Journal:  J Neurol       Date:  2009-04-27       Impact factor: 4.849

Review 5.  [Neurophysiological and neuroimaging studies for restless legs syndrome and periodic leg movement disorder].

Authors:  S Happe; W Paulus
Journal:  Nervenarzt       Date:  2006-06       Impact factor: 1.214

6.  Periodic Leg Movements in Sleep and Restless Legs Syndrome: Considerations in Geriatrics.

Authors:  Donald L Bliwise
Journal:  Sleep Med Clin       Date:  2006-06-01

Review 7.  Sleep-related non epileptic motor disorders.

Authors:  Pasquale Montagna
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

8.  Low Prevalence of Sleep Disorders in Demyelinating Disease in a Northern Tenerife Population.

Authors:  Montserrat González-Platas; Javier González-Platas; Moises Bermúdez-Hernández; Maria Yaiza Pérez-Martín; Cristina Croissier-Elías; Pedro Javier Pérez-Lorensu
Journal:  J Clin Sleep Med       Date:  2016-06-15       Impact factor: 4.062

9.  Genomewide linkage scan identifies a novel susceptibility locus for restless legs syndrome on chromosome 9p.

Authors:  Shenghan Chen; William G Ondo; Shaoqi Rao; Lin Li; Qiuyun Chen; Qing Wang
Journal:  Am J Hum Genet       Date:  2004-04-07       Impact factor: 11.025

10.  Clinical and genetic description of a family with a high prevalence of autosomal dominant restless legs syndrome.

Authors:  Jessica E Young; Carles Vilariño-Güell; Siong-Chi Lin; Zbigniew K Wszolek; Matthew J Farrer
Journal:  Mayo Clin Proc       Date:  2009-02       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.